Mazen Noureddin and Stephen Harrison discuss future directions cost-effectiveness research in and outside the U.S. might take, while the Surfers consider the implications.
Mazen Noureddin describes how he became engaged in studying the cost-effectiveness of widespread NASH screening for diabetics in the US, and what he has found, while the Surfers comment on the value of this pivotal work.
Mazen Noureddin joins the Surfers to discuss his work determining the cost-effectiveness of non-invasive NASH testing and treatment in Type 2 diabetics and the broader population. The discussion shifts to considering broader treatment issues.
Stephen Harrison previews Day Two of NASH-TAG while Ian Rowe, Louise Campbell and Roger Green the issues that each of them anticipate most eagerly
Stephen Harrison previews NASH-TAG 2021, the pre-eminent NASH drug development meeting, which will take place from March 10-12
NEW CONTENT: Suneil Hosmane joins Roger Green to discuss why he found the FDA Webcast so encouraging for liquid biomarkers
Manal Abdelmalek joins the Surfers to share expectations in advance of Friday’s FDA Webcast on NASH Drug Development
The Surfers discuss ways that COVID-19 Vaccine Centers might present an opportunity to educate and screen patients on Liver Health
Evaluating the economic and patient-motivating value of enhanced telemedicine and mobile non-invasive testing technologies in improving NAFLD diagnosis and lowering rates of non-communicable disease
Innovations in Telemedicine and Mobile Technologies are already changing patient care in ways that will remain and expand in the “New Normal” after the COVID-19 pandemic is less urgent
